Huizhou He
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Huizhou He has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Cheneryu Huang
Department of Interventional Radiology The Affiliated Hospital of Guizhou Medical University Guiyang 550004 P. R. China
1 shared publication - Jianqing Peng
State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, School of Pharmaceutical Sciences, Guizhou Medical University, Guiyang, China
1 shared publication - Lei Tang
State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, School of Pharmaceutical Sciences, Guizhou Medical University, China
1 shared publication - Peng Luo
Key Laboratory of Environmental Pollution Monitoring and Disease Control, School of Public Health, Guizhou Provincial Engineering Research Center of Ecological Food Innovation, Guizhou Medical University, Ministry of Education, Guiyang 561113, China
1 shared publication - Runbin Sun
Phase I Clinical Trials Unit Nanjing Drum Tower Hospital Affiliated Hospital of Medical School Nanjing University Nanjing 210008 P. R. China
1 shared publication - Shan Xu
State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine School of Pharmaceutical Sciences Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D Guizhou Medical University Guiyang 561113 P. R. China
1 shared publication
Latest Publications
- Open Access
- 6 March 2025
- Published by Wiley in Advanced Functional Materials
- Vol. 35 (24)
A Novel Protein‐Polysaccharide Oral Nanoemulsion Targeting Activated Hepatic Stellate Cells to Enhance the Therapeutic Effect of Pirfenidone on Fibrosis After Transarterial Chemoembolization for Liver Cancer
Transarterial chemoembolization (TACE) is considered the main treatment for intermediate and advanced liver cancer. Nevertheless, TACE may aggravate liver fibrosis in these patients, which could affect the therapeutic effect after TACE. Pirfenidone (PFD) exhibits significant antifibrotic effects in the liver, primarily via inhibition of hepatic stellate cells (HSCs) activation. However, owing to the high dose required for effective treatment, oral administration of PFD is associated with several side effects. This study introduces an oral folic acid (FA)‐modified protein‐polysaccharide PFD nanoemulsion designed to treat post‐TACE liver fibrosis via liver targeting. This novel PFD oral nanoemulsion withstands gastrointestinal digestion and ensures the gastrointestinal stability of PFD. Furthermore, this nanoemulsion improves the intestinal permeability and antifibrotic efficacy of PFD at a lower dose via folate receptors expressed on both intestinal epithelial cells and activated HSCs. In conclusion, this FA‐modified protein‐polysaccharide nanoemulsion presents a promising approach for oral PFD delivery to effectively ameliorate fibrosis after TACE for liver cancer.
- 6 March 2025
- Published by Wiley in Advanced Functional Materials
- Vol. 35 (24)
Open AccessA Novel Protein‐Polysaccharide Oral Nanoemulsion Targeting Activated Hepatic Stellate Cells to Enhance the Therapeutic Effect of Pirfenidone on Fibrosis After Transarterial Chemoembolization for Liver Cancer
Transarterial chemoembolization (TACE) is considered the main treatment for intermediate and advanced liver cancer. Nevertheless, TACE may aggravate liver fibrosis in these patients, which could affect the therapeutic effect after TACE. Pirfenidone (PFD) exhibits significant antifibrotic effects in the liver, primarily via inhibition of hepatic stellate cells (HSCs) activation. However, owing to the high dose required for effective treatment, oral administration of PFD is associated with several side effects. This study introduces an oral folic acid (FA)‐modified protein‐polysaccharide PFD nanoemulsion designed to treat post‐TACE liver fibrosis via liver targeting. This novel PFD oral nanoemulsion withstands gastrointestinal digestion and ensures the gastrointestinal stability of PFD. Furthermore, this nanoemulsion improves the intestinal permeability and antifibrotic efficacy of PFD at a lower dose via folate receptors expressed on both intestinal epithelial cells and activated HSCs. In conclusion, this FA‐modified protein‐polysaccharide nanoemulsion presents a promising approach for oral PFD delivery to effectively ameliorate fibrosis after TACE for liver cancer.